Based on the current pathology concept as well as therapeutic detail, novel developments will be presented. It is well established that the presence of T cells in the central nervous system (CNS) is indicative of pathology, and that in certain diseases, such as multiple sclerosis, this infiltration disrupts the normal functioning of the nervous system; however, the CNS is no longer seen as an organ having only limited interaction with the peripheral immune system, and specific conditions exist where T lymphocytes infiltrate the brain in order to restore homeostasis. Our focus is on distinct roles and unconventional mechanisms of T lymphocytes interacting with other cells, as well as of cytokines in protection and repair in the CNS, and how these endogenous immune processes could be harnessed to offer new therapeutic strategies. In the late 1990s, it was already reported that inducing an immune response within the CNS might promote repair; however, the molecular mechanism behind this neuroprotective action of T cells has remained largely unknown. Our recent work sheds new light on the underlying mechanism of T-cell-mediated neuroprotection and even regeneration after traumatic CNS injury. The goal of novel therapeutic development is to exploit endogenous repair mechanisms also in multiple sclerosis and, in particular, in chronic progression.
Based on the current pathology concept as well as therapeutic detail, novel developments will be presented. It is well established that the presence of T cells in the central nervous system (CNS) is indicative of pathology, and that in certain diseases, such as multiple sclerosis, this infiltration disrupts the normal functioning of the nervous system; however, the CNS is no longer seen as an organ having only limited interaction with the peripheral immune system, and specific conditions exist where T lymphocytes infiltrate the brain in order to restore homeostasis. Our focus is on distinct roles and unconventional mechanisms of T lymphocytes interacting with other cells, as well as of cytokines in protection and repair in the CNS, and how these endogenous immune processes could be harnessed to offer new therapeutic strategies. In the late 1990s, it was already reported that inducing an immune response within the CNS might promote repair; however, the molecular mechanism behind this neuroprotective action of T cells has remained largely unknown. Our recent work sheds new light on the underlying mechanism of T-cell-mediated neuroprotection and even regeneration after traumatic CNS injury. The goal of novel therapeutic development is to exploit endogenous repair mechanisms also in multiple sclerosis and, in particular, in chronic progression.
L-2
Mechanisms of chronic inflammation secondary progressive multiple sclerosis Shinji Oki National Center of Neurology and Psychiatry, Tokyo, Japan
Genome wide-association studies have clearly showed key roles of helper T (Th) cells and cellular immune responses for development of multiple sclerosis (MS). Novel medication for a "relapsing-remitting" form of MS (RR-MS), including natalizumab and fingolimod, that targets immune cells, such as Th cells, is now available in clinics. However, a significant proportion of RR-MS patients subsequently develop a chronic progressive disease without obvious signs of relapses known as secondary progressive MS (SP-MS). Therapeutic agents for SP-MS are limited and the pathogenesis of SP-MS remains elusive, partly due to the lack of experimental animal models that enable comprehensive and deep analysis of the disease. We have previously reported that an orphan nuclear receptor, NR4A2, plays critical roles on Th17 cells, a key Th cell subset associated with the pathogenesis of RR-MS and its animal model, experimental autoimmune encephalomyelitis (EAE). Although EAE induced in mice lacking the NR4A2 gene in Th cells showed significantly milder signs of acute EAE, they unexpectedly developed a late/chronic EAE, in which atypical Th cells expressing eomesodermin (Eomes) with cytotoxic properties were involved. Functional The clinical course of multiple sclerosis is highly variable. Although many studies have focused on the factors predisposing to the onset of the disease, little consideration has been given for the factors controlling disease course after it is established. In contrast, dysfunctional or exhausted T cells that arise in chronic disease settings; for example, cancer or chronic virus infection, show deficits in effector functions and express high levels of coinhibitory receptors, such as PD-1, suggesting the potential for a new framework for modifying chronic inflammatory disease. In addition to PD-1, tumor-infiltrating lymphocytes have been noted to co-express other coinhibitory receptors (Tim-3, Lag-3, TIGIT), indicating shared regulatory mechanisms driving their expression. In this presentation, a new approach using single-cell RNAseq and cytometry by time of flight to examine the degree of covariance of coinhibitory and costimulatory receptors on both CD4 + and CD8 + T cells at the singlecell level both in vitro and in vivo will be discussed. These findings not only provide insight into the extracellular signals that drive the expression of coinhibitory receptors in T cells, but also provide a platform for the identification of novel molecules and understanding the pathways that lead to dysfunctional T-cell states in cancer and chronic viral infection, as well as overactivation of selfreactive T cells in multiple sclerosis.
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Gastrointestinal influences on multiple sclerosis: translational approaches and beyond Cris Constantinescu Nottingham University Hospitals, Nottingham, UK
The discovery that the cells that mediate autoimmunity in multiple sclerosis (MS), develop in and are controlled by the gut lymphoid tissue (the largest lymphoid organ), and that the microbiota has a major role on this development and control, has led to the study of the role of the gut microbiota in MS. The first study (Yamamura et al.) showed that manipulation of the gut flora (with substantial numerical reduction), induces a natural killer T (NKT) cell-dependent improvement in inflammatory demyelination. Further evidence using transgenic mice was provided by Wekerle's group. Yamamura's group later went on to show specific differences in the gut flora between MS and control populations. As diet is a critical determinant of gut microbiota, this can explain the increased incidence and prevalence of MS in countries where dietary habits have changed. Alterations in the gut microbiota have also been shown in a comprehensive longitudinal study attached to the CLIMB study in the USA. Treatment effects and phenotypic associations are emerging. Whether the gut flora can be manipulated for therapeutic purposes in MS is still unclear. Some experimental approaches are known to alter the gut microbiota and induce regulatory T cells. Examples are Helicobacter pylori and intestinal helminths. The recently completed trial of hookworm for MS by our group could provide an answer. Lifestyle change approaches, such as diet and smoking cessation, might benefit MS in part through their effects on the gut microbiota and gut immune system. Other aspects of gastrointestinal influences in MS will be discussed briefly in this presentation.
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Clinical and magnetic resonance imaging clues and pitfalls in the diagnosis and differential diagnosis of multiple sclerosis Aksel Siva Istanbul University, Istanbul, Turkey
The incidence and prevalence rates of multiple sclerosis (MS) are increasing, so are the number of cases misdiagnosed as MS. One major source of misdiagnosis is misinterpretation of non-specific clinical and imaging findings, and misapplication of MS diagnostic criteria resulting in an overdiagnosis of MS. The diagnostic spectrum of MS and related disorders includes the MS subclinical and clinical phenotypes, MS variants and neuromyelitis optica spectrum disorders, and other antibody-associated atypical inflammatory demyelinating syndromes. The differential diagnosis of MS includes these disorders, as well as some other diseases mimicking MS. There are a number of systemic diseases in which either the clinical or magnetic resonance imaging (MRI) or both findings might mimic MS; however, in most, a well taken history and a through physical examination will reveal the symptoms and signs of the systemic disease, and appropriate laboratory workup will confirm the non-MS diagnosis. As non-specific white matter abnormalities on brain MRI and other imaging findings that can mimic MS, as well as MS-non-specific lesions, might be seen in people with MS, neurologists should be aware of all possibilities, and they should be able to interpret the MRI findings independent of the radiology reports. There are a number of clinical and MRI clues and pitfalls that neurologists should consider in the diagnosis and differential diagnosis of MS in order to reach a proper diagnosis. Currently, the old school of taking a detailed history, a through neurological examination and a cerebrospinal fluid study are essential for MS diagnosis, and MRI is one other tool that is most often confirmatory, but might cause confusion at times too, thus necessitating a "think twice" approach before reaching a final diagnosis. Objective: We previously reported that astroglial connexin (Cx)43, and oligodendroglial Cx32 and Cx47 were frequently lost in acute and chronic lesions of multiple sclerosis and neuromyelitis optica spectrum disorder. However, the roles of glial Cxs in these demyelinating diseases remain to be established. We therefore aimed to clarify glial Cxs' roles in demyelination using experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis, in Cxs-deficient mice. Methods: Tamoxifen was given into Plp1-CreERT; Cx47 fl/fl mice and Glast-CreERT2;Cx43 fl/fl mice to allow tamoxifen-inducible oligodendroglia-specific Cx47 knockout (Cx47 iKO) mice and tamoxifen-inducible gray matter astroglia-specific Cx43 knock-out (GM Cx43 iKO) mice, respectively. Cx30 knock-out (Cx30 KO) mice, Cx47 iKO mice and GM Cx43 iKO mice were used together with their control littermates for induction of EAE by myelin oligodendrocyte glycoprotein. Results: EAE was markedly attenuated in the chronic, but not acute, phase of EAE in Cx30 KO mice, which showed less demyelination and diffuse activation of microglia. These microglia had down-modulation of Toll-like receptor 4 and an M2 phenotype by microarray analysis and immunohistochemistry. In GM Cx43 iKO mice, acute and chronic EAE were significantly ameliorated with less inflammatory cell infiltration and less demyelination. By contrast, Cx47 iKO mice showed more severe EAE at the acute, as well as chronic, phases. Objective: cd T cells play important roles in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis (MS), by producing interleukin (IL)-17 and suppressing the development of regulatory T cells. However, the roles of cd T cells in MS remain to be elucidated. In the present study, we aimed to clarify the role of cd T cells in MS by comprehensive immunophenotyping using flow cytometry. Methods: Peripheral blood mononuclear cells were obtained from 33 untreated MS patients in remission, and 23 age-and gender-matched healthy controls (HC), stained for surface markers and intracellular cytokines, and analyzed by a FACSVerse flow cytometer. Results: In cd T cells, the percentages of Vd2 + cd T cells and Vd2 + Vc9 + cd T cells were significantly decreased in MS patients than in HC, whereas that of Vd1 + cd T cells were significantly increased, resulting in significantly greater Vd1/Vd2 ratios in MS patients than in HC. Furthermore, the percentages of regulatory T cells (CD25 + CD127low/-) in CD4 T cells were significantly decreased in MS patients than in HC. The Vd1/Vd2 ratios negatively correlated with the percentages of regulatory T cells in HC, whereas such an association was lost in MS. The Vd1/Vd2 ratios positively correlated with disease severity defined by Expanded Disability Status Scale scores of Kurtzke in MS patients. The percentages of interleukin-17A-, interferon-c-and both interleukin-17A-and interferon-c-producing Vd2 + cd T cells in the cd T-cell population were significantly decreased in MS patients than in HC. Conclusion: These findings suggest that derangement of cd T cell subsets might contribute to MS severity through insufficient regulation of autoimmune CD4 + T cells by a decreased Vd2 + Vc9 + cd T-cell population.
O-4 Endothelial cell activation induced by immunoglobulin G from patients with neuromyelitis optica and multiple sclerosis on the blood-brain barrier Fumitaka Shimizu, Yasuteru Sano, Yukio Takeshita, Yuka Hamamoto, Toshihiko Maeda, Susumu Fujikawa, Takashi Kanda Department of Neurology and Clinical Neuroscience, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan Objective: Breakdown of the blood-brain barrier (BBB) is an important step in the initiation and progression of disease in neuromyelitis optica (NMO) and multiple sclerosis (MS). Our previous studies showed that NMO or MS sera induced the BBB breakdown using our human in vitro BBB model. The purpose of this study is to identify the role of immunoglobulin G (IgG) from NMO or MS sera in BBB breakdown. Methods: We purified serum IgG from 36 NMO patients (28 acute phase, 8 stable phase) and 34 MS patients (8 acute phase, 16 stable phase, 10 secondary progressive phase) and 20 healthy controls. IgG was exposed to the human brain microvascular endothelial cells (TY10) and the amount of nuclear factor (NF)-jB p65-positive cells was analyzed using a high-content imaging system. Results: Five IgG from the acute NMO patients (3 anti-AQP4-positive NMO and 2 anti-myelin oligodendrocyte glycoprotein-positive NMO) significantly induced nuclear translocation of NF-jB p65, compared with those from healthy controls. A significant correlation between the amounts of NF-jB nuclear-positive cells and gadolinium enhancement on magnetic resonance imaging was observed in NMO. Furthermore, nine MS-IgG (2/8 acute MS, 5/9 SPMS, 2/16 stable MS) showed the significant increase in the induction of NF-jB p65 translocation. Conclusions: We identified IgG from NMO and MS patients that have a biological effect on BBB endothelial cells. Further analysis using the method of liquid chromatography-tandem mass spectrometry will be need to identify the novel BBB antigen against antibodies in the IgG of patients with NMO and MS. Although most subtypes of EDS are diagnosed based on molecular confirmation with identification of causative variants in the respective genes, the molecular basis on hypermobile EDS remains to be identified. It was recently proposed that diverse clinical features of EDS, including neurological and immunological manifestations, can be attributed to the mast cell activation. Chronic pain is one of the major neurological findings, resulting in decreased physical activities and quality of life in patients with EDS. The underlying mechanism of chronic pain in EDS is mainly described as the combination of nociceptive and neuropathic pain, attributed to musculoskeletal disorders and polyneuropathy, respectively. However little is known about the involvement of the central nervous system in the pain of EDS. We report two hypermobile EDS patients with chronic pain that showed relapsing neurological exacerbations: paraplegia, visual impairment, intractable nausea and vomiting. They were diagnosed with comorbidity between hypermobile EDS and multiple sclerosis/seronegative neuromyelitis optica spectrum disorders. Intravenous high-dose corticosteroid was partially effective for acute attacks. Notably, plasmapheresis (immunoadsorption plasmapheresis and plasma exchange) showed a marked improvement for chronic refractory pain and visual impairment in both patients, resulting in tapered pain medications, including opioids. The unexpected therapeutic efficacy suggests that the neurological manifestations, including chronic pain, in EDS can be mediated by an immunological mechanism.
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P-2 Drug-induced progressive multifocal leukoencephalopathy in multiple sclerosis Motohiro Yukitake Saga Central Hospital, Saga, Japan
Objective: To clarify the latest incidence, risk factors and characteristics in drug-induced progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS). Methods: Manuscripts and data about drug-induced PML in MS were found using PubMed and so on. In the patients treated with fingolimod, we investigated the initial age of onset, sex, relapse rate per year, and side-effects and the treatment for them. This study was carried out in accordance with the Human Research Guideline of the Internal Ethics Review Board of our hospital.
Results: The average age of onset was 31.3 AE 10.5, the male-to-female sex ratio was 3:9 and the average relapse rate was 0.46 per year. Three cases discontinued fingolimod due to skin rash, bradycardia or they were suspected to have progressive multifocal leukoencephalopathy. In three cases, we withheld medication on some days of a week due to lymphopenia. In two cases with liver dysfunction, one patient recovered from the administration of ursodeoxycholic acid, and the other from the decreased number of medication days. Due to difficulty with medication management, we administered one patient receiving home-visit nursing and instruction from the pharmacist. Conclusion: For the safe continuation of fingolimod, we recommend understanding the management of its sideeffects, in cooperation with regional medication care services. Disability in multiple sclerosis (MS) patients is typically assessed using the Expanded Disability Status Scale (EDSS). However, that scale does not necessarily reflect activities of daily living (ADL), which might be more appropriately evaluated by the modified Rankin Scale (mRS) or Barthel Index (BI) score. We previously found that an EDSS score of 4.5, the current criterion for severe disease status in Japan, corresponded to an mRS score of 3 in 184 Japanese patients with relapsing-remitting MS. In the present study, another 28 patients with secondary progressive MS and seven patients with primary progressive MS were found to be significantly different from those previously reported relapsing-remitting MS patients in terms of EDSS, mRS and BI scores. In contrast, the mean scores of those three clinical scales were similar between the secondary progressive MS and primary progressive MS groups (EDSS 6.0 vs 5.4, mRS 3.3 vs 3.1, BI 75 vs 80). Thus, we grouped the secondary progressive MS and primary progressive MS patients into progressive-type MS, and attempted to elucidate factors of ADL, assessed using BI, that have effects on EDSS and mRS scores. BI score was found to be inversely correlated with EDSS (r = -0.744) and mRS (r = -0.85) scores, and the ADL items that showed a major impact on EDSS and mRS were "transfer from wheelchair," "walking" and "using stairs." In contrast, bowel incontinence had the least impact.
In patients with progressive type MS, major factors affecting ADL seem to be associated with lower extremity function.
P-6
Overlap between limbic encephalitis and demyelinating diseases: anti-N-methyl-D-aspartatereceptor antibody-negative case Yasuyuki Takai, Yoko Warabi, Ryohei Norioka, Maya Tojima, Jun Ikezawa, Ryoichi Okiyama, Eiji Isozaki Department of Neurology, Tokyo Metropolitan Neurological Hospital, Tokyo, Japan
Background: An overlap has been recognized between anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis and demyelinating diseases. We report the case of a 19-year-old male patient who was negative for anti-NMDAR antibody and presented with limbic lesions together with demyelinated lesions. Case: The patient developed numbness in the left upper extremity, which disappeared without treatment at 17 years-of-age. He transiently presented with loss of short-term memory after a motorbike accident at 18 yearsof-age. At 19 years-of-age, he developed loss of short-term memory again, followed by paralysis and sensory disturbance in the left upper and lower extremities. Magnetic resonance brain fluid-attenuated inversion recovery/T2-weighted imaging showed diffuse high-intensity lesions in the medial parts of both temporal lobes with spotty multiple lesions in the periventricular and subcortical white matter. Twenty days later, a new lesion appeared around the right putamen, whereas the temporal lesions disappeared. With gadolinium enhancement, a symptomatic cervical lesion was found at C3, involving one vertebral segment. Cerebrospinal fluid analysis revealed no pleocytosis or elevated protein level, but showed oligoclonal immunoglobulin G bands. There were no antibodies against aquaporin-4, myelin oligodendrocyte glycoprotein, and NMDAR in the serum and cerebrospinal fluid samples, and no findings suggestive of viral infection or rheumatoid vasculitis. Corticosteroid treatment was effective for the symptom of his extremities, but not for the memory impairment. Conclusion: Our case suggests the existence of an overlap between limbic encephalitis and demyelinating diseases in anti-NMDAR antibody-negative cases. Further investigation of patients is required to clarify the pathological mechanisms of neuro-immune diseases.
P-7
Neurosarcoidosis and neuromyelitis optica spectrum disorders compared using T2*-weighted imaging of the head Ryusei Nishigori, Youko Warabi, Eiji Isozaki Tokyo Metropolitan Neurological Hospital, Tokyo, Japan
Background: Neurosarcoidosis and neuromyelitis optica spectrum disorders (NMOSD) are sometimes difficult to distinguish based on magnetic resonance imaging findings, especially in cases of longitudinally extensive myelitis. Method: We retrospectively examined adult patients with neurosarcoidosis or NMOSD who visited our hospital between 2013 and 2017. Neurosarcoidosis had been diagnosed in these patients based on the Japanese sarcoidosis clinical or pathological criteria and the presence of spinal lesions or cranial nerve paralysis. NMOSD was diagnosed based on the criteria for NMOSD with aquaporin-4 immunoglobulin G. The clinical characteristics and head magnetic resonance imaging findings of each group were analyzed and compared.
Results: A total of 10 patients with neurosarcoidosis and 26 patients with NMOSD underwent T2 star-weighted imaging (T2* WI) of the head within a year of the disease onset, which showed a hemorrhagic lesion in six patients with neurosarcoidosis. Five of these patients had a subcortical or brainstem microhemorrhage, and one patient had a thalamic hemorrhage. Only one NMOSD patient had a microhemorrhage in the left cerebellar hemisphere on T2* WI. The number of neurosarcoidosis lesions on T2* WI was significantly greater than that of NMOSD lesions (P = 0.0007; Fisher's exact test). Discussion: A dysfunction of the blood-brain barrier is thought to be involved in the development of central nervous lesions in sarcoidosis. Our findings might therefore be related to the etiology of neurosarcoidosis. The present study suggests that T2* WI of the head might be useful for distinguishing neurosarcoidosis from NMOSD, and even in myelitis cases, it might show hemorrhagic lesions.
